Travere Therapeutics (TVTX) Competitors $15.63 +0.18 (+1.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.23 -0.40 (-2.56%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. RYTM, CRSP, AXSM, TLX, LNTH, PCVX, MTSR, CYTK, MRUS, and KRYSShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), Lantheus (LNTH), Vaxcyte (PCVX), Metsera (MTSR), Cytokinetics (CYTK), Merus (MRUS), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Its Competitors Rhythm Pharmaceuticals CRISPR Therapeutics Axsome Therapeutics Telix Pharmaceuticals Lantheus Vaxcyte Metsera Cytokinetics Merus Krystal Biotech Travere Therapeutics (NASDAQ:TVTX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Do analysts recommend TVTX or RYTM? Travere Therapeutics currently has a consensus target price of $32.14, indicating a potential upside of 105.65%. Rhythm Pharmaceuticals has a consensus target price of $91.93, indicating a potential upside of 4.11%. Given Travere Therapeutics' higher possible upside, analysts plainly believe Travere Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Is TVTX or RYTM more profitable? Travere Therapeutics has a net margin of -82.88% compared to Rhythm Pharmaceuticals' net margin of -123.26%. Rhythm Pharmaceuticals' return on equity of -739.62% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-82.88% -1,179.73% -41.10% Rhythm Pharmaceuticals -123.26%-739.62%-44.27% Does the media refer more to TVTX or RYTM? In the previous week, Rhythm Pharmaceuticals had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 12 mentions for Rhythm Pharmaceuticals and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.95 beat Rhythm Pharmaceuticals' score of 0.78 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, TVTX or RYTM? Rhythm Pharmaceuticals has lower revenue, but higher earnings than Travere Therapeutics. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$233.18M5.95-$321.55M-$2.81-5.56Rhythm Pharmaceuticals$130.13M43.17-$260.60M-$2.81-31.42 Which has more risk & volatility, TVTX or RYTM? Travere Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. SummaryRhythm Pharmaceuticals beats Travere Therapeutics on 8 of the 14 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.37B$3.00B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-5.5617.7428.8323.83Price / Sales5.95179.21372.0766.02Price / CashN/A41.9535.4557.96Price / Book20.578.508.275.54Net Income-$321.55M-$55.06M$3.25B$259.28M7 Day Performance2.02%-3.99%-3.73%-4.68%1 Month Performance5.32%9.58%4.29%4.36%1 Year Performance73.67%6.70%25.87%17.88% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics1.9209 of 5 stars$15.63+1.2%$32.14+105.6%+69.2%$1.37B$233.18M-5.56460Short Interest ↑RYTMRhythm Pharmaceuticals3.5511 of 5 stars$88.63-0.6%$91.93+3.7%+88.5%$5.68B$130.13M-31.54140Upcoming EarningsInsider TradeCRSPCRISPR Therapeutics2.8206 of 5 stars$65.33+0.3%$71.75+9.8%+2.3%$5.62B$37.31M-14.45460Upcoming EarningsAnalyst RevisionGap DownHigh Trading VolumeAXSMAxsome Therapeutics4.8236 of 5 stars$109.68-1.8%$172.33+57.1%+19.8%$5.50B$385.69M-19.01380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$16.50+1.7%$22.33+35.4%N/A$5.49B$516.72M0.00N/AHigh Trading VolumeLNTHLantheus4.6193 of 5 stars$71.56+2.0%$131.20+83.3%-28.4%$4.86B$1.53B20.33700News CoveragePositive NewsUpcoming EarningsAnalyst RevisionPCVXVaxcyte2.2389 of 5 stars$35.64-1.6%$136.50+283.0%-58.0%$4.67BN/A-8.93160News CoveragePositive NewsUpcoming EarningsMTSRMetseraN/A$39.91-6.6%$55.00+37.8%N/A$4.49BN/A0.0081News CoverageEarnings ReportLockup ExpirationAnalyst RevisionGap UpCYTKCytokinetics4.0943 of 5 stars$36.96-0.7%$70.92+91.9%-36.6%$4.45B$18.47M-6.99250News CoverageUpcoming EarningsAnalyst ForecastInsider TradeMRUSMerus2.9208 of 5 stars$62.37-1.4%$84.64+35.7%+25.1%$4.38B$54.73M-15.2937News CoverageUpcoming EarningsKRYSKrystal Biotech4.8923 of 5 stars$148.09+0.4%$213.75+44.3%-21.0%$4.26B$290.52M35.60210Upcoming Earnings Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors CRISPR Therapeutics Competitors Axsome Therapeutics Competitors Telix Pharmaceuticals Competitors Lantheus Competitors Vaxcyte Competitors Metsera Competitors Cytokinetics Competitors Merus Competitors Krystal Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVTX Stock Alerts